Oligonucleotide Synthesis Market Forecast Signals Strong Expansion During 2025-2032 | Persistence Market Research

The oligonucleotide synthesis market has evolved from a niche research-support function into a strategic pillar of modern biotechnology and pharmaceutical development. Oligonucleotides-short, synthetically produced DNA or RNA sequences-are indispensable in applications ranging from basic genetic research and molecular diagnostics to advanced therapeutics such as antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and RNA- and DNA-based vaccines. As precision medicine continues to reshape healthcare, the ability to reliably synthesize high-quality, customized oligonucleotides at scale has become a critical enabler of innovation. The market is benefiting from sustained demand across academic research institutes, biotechnology companies, contract development and manufacturing organizations (CDMOs), and large pharmaceutical firms pursuing nucleic acid-based drug pipelines.

Download Your Free Sample & Explore Key Insights: https://www.persistencemarketresearch.com/samples/3296

From a quantitative perspective, the global oligonucleotide synthesis market is likely to be valued at approximately US$5.3 billion in 2025 and is projected to reach US$13.5 billion by 2032, expanding at a robust compound annual growth rate (CAGR) of 14.2% during the forecast period. This strong trajectory reflects accelerating adoption of oligonucleotide-based therapeutics, increasing regulatory approvals, and rising investments in next-generation synthesis platforms. North America is expected to remain the leading geographical region with over 40% value share in 2025 due to its established GMP manufacturing infrastructure, strong regulatory support, and high demand for therapeutic oligos. In terms of market leadership by segment, custom-synthesized oligonucleotides dominate revenue generation, driven by their versatility across research, diagnostics, and therapeutics, while the therapeutic application segment continues to outpace others as clinical pipelines expand and commercialization efforts intensify.

Key Highlights from the Oligonucleotide Synthesis Market Report

• The global oligonucleotide synthesis market is projected to grow at a CAGR of 14.2% from 2025 to 2032, reflecting strong momentum across therapeutic and research applications.
• North America is expected to lead the market with more than 40% value share in 2025 due to advanced R&D infrastructure and regulatory clarity.
• Asia Pacific is the fastest-growing region, supported by expanding CDMO capacity, rising R&D investments, and increasing adoption of RNA- and DNA-based therapeutics.
• Custom-synthesized oligonucleotides represent the dominant product type, driven by precision requirements in diagnostics, gene editing, and therapeutics.
• Therapeutic oligonucleotides account for the largest application share, fueled by expanding clinical pipelines and growing regulatory approvals.
• Automation and scalable manufacturing technologies are emerging as critical differentiators for cost efficiency and regulatory compliance.

Market Segmentation Analysis

The oligonucleotide synthesis market is segmented across multiple dimensions, including product type, oligonucleotide type, application, and end-user, each reflecting distinct demand drivers and growth dynamics. By product type, oligonucleotides themselves account for the largest share of market revenue, supported by their extensive use in gene expression studies, RNA interference, and molecular diagnostics. Their relevance continues to grow as genetic testing, sequencing technologies, and nucleic acid-based therapies become more integrated into mainstream healthcare and life science research.

When analyzed by oligonucleotide type, custom-synthesized oligonucleotides emerge as the leading segment. These tailored sequences are designed to meet specific experimental or therapeutic requirements, making them indispensable for applications such as CRISPR-based gene editing, personalized diagnostics, and targeted therapeutics. The demand for custom oligos is closely linked to the rise of personalized medicine and the growing emphasis on precision-driven research methodologies. Standard or pre-designed oligonucleotides also maintain steady demand, particularly in routine laboratory workflows, but lack the growth acceleration seen in customized offerings.

From an application standpoint, therapeutic oligonucleotides represent the largest and fastest-growing segment of the market. Antisense oligonucleotides, siRNAs, and other RNA-based drugs are increasingly used to modulate gene expression and treat conditions previously considered untreatable, including rare genetic disorders and certain chronic diseases. Research and diagnostic applications form another significant segment, as oligonucleotides remain foundational tools in PCR, sequencing, microarrays, and molecular assays. End-user segmentation further highlights strong adoption among pharmaceutical and biotechnology companies, followed by academic and research institutions, while diagnostic laboratories and contract research organizations contribute to incremental growth.

Regional Insights into the Oligonucleotide Synthesis Market

Regional analysis reveals significant variation in market maturity, growth rates, and strategic priorities. North America remains the most prominent market, projected to capture approximately 42.1% of global share in 2025. The region's dominance is underpinned by a well-established biotechnology ecosystem, extensive funding for life sciences research, and clear regulatory frameworks for nucleic acid-based therapies. The United States, in particular, leads in individualized antisense oligonucleotide programs and benefits from supportive initiatives such as the FDA's guidance on noncommercial ASO development. Collaborative models like the N=1 Collaborative further reinforce the region's leadership by accelerating customized gene-targeting therapies and setting precedents for broader therapeutic applications.

Europe represents another critical market, accounting for nearly 28.8% of global share in 2025. The region's strength lies in its collaborative research culture, robust public funding mechanisms, and strong emphasis on translational medicine. Pan-European initiatives such as ON-TRACT and the 1 Mutation 1 Medicine platform are advancing oligonucleotide-based treatments while addressing challenges related to delivery, stability, and off-target effects. Europe's focus on ethical testing, sustainability, and regulatory dialogue creates a balanced ecosystem that supports both innovation and long-term scalability in oligonucleotide synthesis.

The Asia Pacific region is emerging as the fastest-growing market, with a projected CAGR of 17.8% during the forecast period. Growth is driven by expanding CDMO infrastructure, increasing government and private investments in biotechnology, and rising demand for nucleic acid therapeutics. Strategic partnerships and facility expansions, such as new cGMP manufacturing plants and licensing agreements for advanced RNA chemistries, are positioning Asia Pacific as a global hub for scalable and cost-effective oligonucleotide production. Countries within the region are increasingly focusing on high-quality manufacturing standards, reinforcing their role in the global supply chain.

Get Custom Insights Designed for Your Business: https://www.persistencemarketresearch.com/request-customization/3296

Market Drivers Shaping Industry Expansion

The primary driver of growth in the oligonucleotide synthesis market is the rapid expansion of therapeutic pipelines based on nucleic acid technologies. As of March 2025, approximately 20 oligonucleotide-based drugs have received global regulatory approvals, with numerous candidates progressing through clinical and preclinical stages. These therapies offer novel mechanisms of action, enabling precise gene silencing or modulation and opening new treatment avenues for rare genetic disorders, oncology, and chronic diseases. Increasing clinical success has strengthened confidence among regulators, investors, and healthcare providers, further accelerating adoption.

Another significant driver is the surge in investment and funding activity across the oligonucleotide ecosystem. High-profile financing rounds, such as multi-million-dollar Series A and B investments in companies developing antisense and RNA-targeted therapies, highlight strong investor confidence in the long-term potential of the market. These investments support not only drug development but also expansion of manufacturing capacity, process optimization, and technology innovation, all of which contribute to sustained market growth.

Market Restraints and Operational Challenges

Despite strong growth prospects, the oligonucleotide synthesis market faces notable restraints related to technological complexity, cost, and scalability. The industry-standard phosphoramidite-based solid-phase synthesis process, while reliable for short sequences, becomes increasingly inefficient for longer oligonucleotides due to declining yields, higher error rates, and extensive purification requirements. The process is also resource-intensive, relying on toxic solvents and generating significant waste, which raises both cost and sustainability concerns.

Cost remains a critical barrier, particularly for therapeutic-grade oligonucleotides. The production of siRNA or complex modified oligos can involve hundreds of synthesis steps and consume large quantities of raw materials, resulting in active pharmaceutical ingredient costs exceeding US$1 million per kilogram in some cases. These economic constraints limit broader commercialization and confine many oligonucleotide therapies to rare disease indications, restricting market penetration and slowing adoption in larger patient populations.

Market Opportunities and Future Growth Potential

The market presents substantial opportunities driven by automation, digital integration, and next-generation synthesis technologies. Automated platforms equipped with process analytical technologies are transforming oligonucleotide manufacturing by improving reproducibility, reducing manual errors, and enabling real-time quality control. These advancements not only lower production costs but also facilitate regulatory compliance, making large-scale commercial manufacturing more feasible.

Beyond technology, expanding therapeutic applications offer significant growth potential. Oligonucleotides are increasingly used in vaccines, gene editing, and molecular diagnostics, extending demand beyond traditional research settings. As antisense and RNA-based therapies move toward broader indications, the need for scalable, high-throughput, and cost-effective synthesis solutions will intensify. This convergence of technological innovation and expanding clinical demand positions the oligonucleotide synthesis market as a critical growth frontier within modern biotechnology.

Company Insights and Competitive Landscape

The global oligonucleotide synthesis market is highly competitive, characterized by continuous capacity expansions, strategic partnerships, and investments in automation and high-throughput platforms. Leading companies are strengthening their positions by integrating synthesis, purification, and delivery capabilities to serve therapeutic, diagnostic, and research markets worldwide.

Checkout Now & Download Complete Market Report: https://www.persistencemarketresearch.com/checkout/3296

Key Players Operating in the Oligonucleotide Synthesis Market:

• Integrated DNA Technologies, Inc.
• GenScript Biotech Corporation
• Eurofins Scientific SE
• Bioneer Corporation
• Kaneka Corporation (Eurogentec)
• Biolegio B.V.
• Eton Bioscience, Inc.
• IBA GmbH
• Quintara Biosciences
• LGC Biosearch Technologies
• Thermo Fisher Scientific, Inc.
• TriLink BioTechnologies, LLC
• TAG Copenhagen A/S
• PolyGen GmbH
• General Electric Co.
• BioAutomation
• Biolytic Lab Performance Inc.
• Others

Recent market developments underscore the pace of innovation and expansion. In May 2025, Oligo Factory launched low-scale oligonucleotide synthesis services to support therapeutic and diagnostic development across discovery and preclinical stages. Earlier, in December 2024, Codexis completed construction of its ECO Synthesis Innovation Lab, aimed at advancing enzymatic oligonucleotide manufacturing and producing GLP-grade materials for preclinical studies.

Conclusion

The oligonucleotide synthesis market stands at the intersection of biotechnology innovation, precision medicine, and advanced manufacturing. Strong growth fundamentals-driven by expanding therapeutic pipelines, increasing regulatory approvals, and rising investments-are reshaping the industry's scale and scope. While technological and cost-related challenges persist, ongoing advancements in automation, process efficiency, and scalable manufacturing are steadily addressing these constraints. As oligonucleotides continue to gain prominence across therapeutics, diagnostics, and research, the market is poised for sustained expansion, solidifying its role as a cornerstone of next-generation life sciences and healthcare innovation.

Read More Related Reports:

Influenza Diagnostics Market https://www.persistencemarketresearch.com/market-research/influenza-diagnostics-market.asp
Fill-finish Pharmaceutical Contract Manufacturing Market https://www.persistencemarketresearch.com/market-research/fill-finish-pharmaceutical-contract-manufacturing-market.asp
Neuroscience Market https://www.persistencemarketresearch.com/market-research/neuroscience-market.asp
Infection Surveillance Solutions Market https://www.persistencemarketresearch.com/market-research/infection-surveillance-solutions-market.asp

Contact Us:

Persistence Market Research
Second Floor, 150 Fleet Street, London, EC4A 2DQ, United Kingdom
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.